Global brokerage Bernstein forecasts a decade of growth for Indian biopharma, driven by complex therapies and AI. The firm favors Zydus Lifesciences, Lupin, and Sun Pharma while expressing caution on others based on long-term innovation potential.
Global brokerage firm Bernstein has launched its coverage of the Indian healthcare sector, predicting a significant transformation over the next ten years. The research identifies a shift from traditional generic drug manufacturing toward complex, specialized therapies. According to Bernstein, this evolution could expand the Indian biopharma market to approximately $195 billion by leveraging global demand for specialized treatments and new manufacturing capabilities.
Growth Drivers in Specialized Therapies
The brokerage highlights specific areas that are likely to drive this expansion. These include the development of drug-device combinations, metabolic peptides, and advanced technologies such as RNA and cellular therapies like CAR-T. These niches are categorized as areas where incremental innovation can provide a business advantage. Beyond product development, the firm notes that the integration of generative AI in research and manufacturing processes could improve efficiency. Estimates suggest these technological improvements may contribute to a 3-4 percentage point expansion in profit margins for companies that successfully adopt them.
Strategic Outlook on Market Players
Bernstein has issued positive outlooks for several major pharmaceutical companies, naming Zydus Lifesciences, Lupin, and Sun Pharma as top beneficiaries of these sector-wide changes. Conversely, the firm provided a more cautious stance on Biocon and Mankind Pharma, suggesting that these companies may face challenges that keep their growth potential behind peers. Aurobindo Pharma was given a neutral rating. These views are based on the firm’s assessment of how well each company is positioned to handle the transition toward higher-value products and more sophisticated manufacturing standards.
Sector Valuation and Market Context
While the Nifty Pharma index is currently trading above its long-term average price-to-earnings (P/E) multiple of roughly 30.5x, Bernstein suggests that valuations for some of its preferred stocks do not fully reflect their long-term potential. The firm argues that the broader market might be placing too much emphasis on current U.S. generic pricing pressure and domestic regulatory hurdles. By focusing on these near-term obstacles, investors may be overlooking the potential revenue gains from the six identified innovation areas, which the brokerage expects could add $70-75 billion to the industry size over the coming decade.
Investors may monitor the actual adoption rates of AI in R&D and the success of these companies in securing regulatory approvals for complex drugs, which serve as the primary execution risks for this growth thesis. Tracking the profit margin performance in upcoming quarterly results will also reveal whether the expected operational efficiencies from new technology are materializing as forecasted.